Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.

Loading...
Thumbnail Image
Authors
Bowman, Pamela
Shepherd, Maggie
Ellard, Sian
Hattersley, Andrew T.
Journal
The Lancet. Diabetes & Endocrinology
Type
Journal Article
Publisher
Elsevier
Rights
Archived with thanks to The lancet. Diabetes & endocrinology. This is an Open Access article under the CC BY 4.0 license.
KCNJ11 mutations cause permanent neonatal diabetes through pancreatic ATP-sensitive potassium channel activation. 90% of patients successfully transfer from insulin to oral sulfonylureas with excellent initial glycaemic control; however, whether this control is maintained in the long term is unclear. Sulfonylurea failure is seen in about 44% of people with type 2 diabetes after 5 years of treatment. Therefore, we did a 10-year multicentre follow-up study of a large international cohort of patients with KCNJ11 permanent neonatal diabetes to address the key questions relating to long-term efficacy and safety of sulfonylureas in these patients.
Citation
Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. 2018 Aug;6(8):637-646. Epub 2018 Jun 4. Lancet Diabetes Endocrinol
Note
This article is available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.